Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Cited by (370)

Items 201–300 of 370

1. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
   Ying-Dan Wang, Aihua Hao, Ping Ji, Yunping Ma, Zhaoyong Zhang, Jiali Chen, Qiyu Mao, Xinyi Xiong, Palizhati Rehati, Yajie Wang et al. · 2024 · Nature Communications
2. Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies
   Tal Noy-Porat, Avishay Edri, Ron Alcalay, Efi Makdasi, David Gur, Moshe Aftalion, Yentl Evgy, Adi Beth-Din, Yinon Levy, Eyal Epstein et al. · 2021 · Antibodies
3. Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence
   Francisco Fuentes‐Villalobos, José Luis Velasco Garrido, Matías A. Medina, Nicole Zambrano, Natalia Ross, Felipe Bravo, Aracelly Gaete-Argel, Aarón Oyarzún-Arrau, Fatima Amanat, Ricardo Soto‐Rifo et al. · 2022 · Frontiers in Immunology
4. IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
   Pavel A. Nikitin, Jillian M. DiMuzio, John P. Dowling, Nirja B. Patel, Jamie L. Bingaman, Baron C. Heimbach, Noeleya Henriquez, Chris Nicolescu, Antonio M Polley, Eden L. Sikorski et al. · 2022 · Science Immunology
5. Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
   Jorge Calderón‐Parra, Pablo Guisado‐Vasco, Rocío Montejano, Vicente Estrada, Guillermo Cuevas, José Aguareles, José Ramón Arribas, Marta Erro Iribarren, Marina Calvo‐Salvador, Ana Fernández‐Cruz et al. · 2023 · Journal of Clinical Medicine
6. Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions
   Yannic C. Bartsch, Deniz Cizmeci, Jaewon Kang, Hailong Gao, Wei Shi, Abishek Chandrashekar, Ai-ris Yonekura Collier, Bing Chen, Dan H. Barouch, Galit Alter · 2023 · iScience
7. Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population
   Gregory D. Gromowski, Camila Macedo Cincotta, Sandra Vanderli Mayer, Jocelyn King, Isabella Swafford, Michael K. McCracken, Dante Coleman, Jennifer Enoch, Casey K. Storme, Janice M. Darden et al. · 2023 · EBioMedicine
8. Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D
   Matthew D. Slein, Iara M. Backes, Callaghan R. Garland, Natasha S. Kelkar, David A. Leib, Margaret E. Ackerman · 2024 · Cell Reports Medicine
9. PGLYRP1-mIgG2a-Fc inhibits macrophage activation via AKT/NF-κB signaling and protects against fatal lung injury during bacterial infection
   Yan Jia, Shan Ren, Luyao Song, Siyi Wang, Wei Han, Jingjing Li, Yan Yu, Buyong Ma · 2023 · iScience
10. Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities
    Lili Wang, Chuang Li, Wanting Li, Liwei Zhao, Tiantian Zhao, Lin Chen, Ming Li, Jing Fan, Jiayan Li, Chao Wu et al. · 2023 · Emerging Microbes & Infections
11. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
    The CONCOR-1 Study Group, Philippe Bégin, Jeannie L. Callum, Erin Jamula, Richard J. Cook, Nancy M. Heddle, Alan T. Tinmouth, Michelle P. Zeller, Guillaume Beaudoin-Bussières, Luiz Amorim et al. · 2021 · medRxiv
12. An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice
    G. Beaudoin-Bussières, Yao-Zong Chen, Irfan Ullah, Jérémie Prévost, W. Tolbert, K. Symmes, Shi-Lei Ding, M. Benlarbi, S. Gong, A. Tauzin et al. · 2021 · bioRxiv
13. Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses
    Megi Rexhepaj, Daniel E. Asarnow, Lisa Perruzza, Young‐Jun Park, Barbara Guarino, Mathew Mccallum, Katja Culap, Christian Saliba, Giada Leoni, Alessio Balmelli et al. · 2024 · Immunity
14. Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
    Alberto Alape‐Girón, Andrés Moreira‐Soto, Mauricio Arguedas, Hebleen Brenes, Willem Buján, Eugenia Corrales‐Aguilar, Cecilia Díaz, Ann Echeverri, Marietta Flores-Dı́az, Aarón Gómez et al. · 2021 · Frontiers in Medicine
15. SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement
    Ying-Ting Wang, ROBERT DAY ALLEN, Kenneth Kim, Norazizah Shafee, Andrew Gonzalez, Michael N. Nguyen, Kristen M. Valentine, Xia Cao, Lucy Lu, Chin-I Pai et al. · 2021 · Antiviral Research
16. Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features
    Hao D. Cheng, Karen G. Dowell, Chris Bailey‐Kellogg, Brittany A. Goods, John Christopher Love, Guido Ferrari, Galit Alter, Johannes S. Gach, Donald N. Forthal, George K. Lewis et al. · 2021 · Retrovirology
17. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD
    Yaozong Chen, Jérémie Prévost, Irfan Ullah, Hugo Romero, Véronique Lisi, William David Tolbert, Jonathan R. Grover, Shilei Ding, Shang Yu Gong, Guillaume Beaudoin-Bussières et al. · 2022 · iScience
18. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew J. Koch, Kathryn E. Foulds et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
19. Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses
    Jerry C H Tam, Abbie C. Sibayan, Jeffrey Seow, Carl Graham, Ashwini Kurshan, Blair Merrick, Richard James Stanton, Katie J. Doores · 2025 · Cell Reports
20. Mapping ACE2 and TMPRSS2 co-expression in human brain tissue: implications for SARS-CoV-2 neurological manifestations
    Tulika Gupta, Munish Kumar, Ujjwal Jit Kaur, Asha Rao, Ranjana Bharti · 2024 · Journal of NeuroVirology
21. Development of flow cytometry‐based assays to assess the ability of antibodies to bind to SARS‐CoV‐2‐infected and spike‐transfected cells and mediate NK cell degranulation
    Dieter Mielke, Sherry A. Stanfield-Oakley, Shalini Jha, Taylor Keyes, Adam Zalaquett, Brooke Dunn, Nicole S. Rodgers, Thomas H. Oguin, Gregory D. Sempowski, Raquel A. Binder et al. · 2022 · Cytometry Part A
22. T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
    Chang Chu, Anne Schönbrunn, Saban Elitok, Florian Kern, Karsten Schnatbaum, Holger Wenschuh, Kristin Klemm, Volker von Baehr, Bernhard Karl Krämer, Berthold Hocher · 2022 · Clinica Chimica Acta
23. Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
    Zhiqiang Ku, Xuping Xie, Jianqing Lin, Peng Gao, Abbas El Sahili, Hang Su, Yang Liu, Xiaohua Ye, Xin Li, Xuejun Fan et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
24. Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates
    Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, Dillon R. Flebbe, Anna Mychalowych, Evan Lamb, Meredith E. Davis-Gardner, Matthew R. Burnett, Leonid Serebryannyy, Bob C. Lin et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
25. A Structural Voyage Toward the Landscape of Humoral and Cellular Immune Escapes of SARS ‐ CoV ‐2
    Jun Liu, Yan Wu, George F. Gao · 2025 · Immunological Reviews
26. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern
    Chang-Kyu Heo, Won-Hee Lim, Jihyun Yang, Sumin Son, Sang Jick Kim, Doo‐Jin Kim, Haryoung Poo, Eun‐Wie Cho · 2023 · Frontiers in Immunology
27. Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
    Jennifer L. Schwedler, Maxwell A. Stefan, Christine E. Thatcher, Peter R. McIlroy, Anupama Sinha, Ashlee M. Phillips, Christopher A. Sumner, Colleen M. Courtney, Christina Y. Kim, Dina R. Weilhammer et al. · 2024 · mAbs
28. SARS-CoV-2–Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals
    Yanling Liu, P. Budylowski, Shilan Dong, Zhi-Jie Li, S. Goroshko, Leslie Y. T. Leung, E. Grunebaum, P. Campisi, E. Propst, N. Wolter et al. · 2021 · Journal of Immunology
29. Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
    Yukiya Kurahashi, Silvia Sutandhio, Koichi Furukawa, Lidya Handayani Tjan, Sachiyo Iwata, Shigeru Sano, Yoshiki Tohma, Hiroyuki Ohkita, Sachiko Nakamura, Mitsuhiro Nishimura et al. · 2022 · Frontiers in Immunology
30. Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2
    Harini Natarajan, Shiwei Xu, Andrew R. Crowley, Savannah E. Butler, Joshua A. Weiner, Evan M. Bloch, Kirsten E. Littlefield, Sarah E. Benner, Ruchee Shrestha, Olivia Ajayi et al. · 2022 · BMC Immunology
31. Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement
    Zenjiro Sampei, Christine X. Koo, Frannie Jiuyi Teo, Ying Xiu Toh, Taku Fukuzawa, Siok Wan Gan, Takeru Nambu, Adrian W. S. Ho, Kiyofumi Honda, Tomoyuki Igawa et al. · 2023 · Antibodies
32. SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties
    Craig W. Fenwick, Priscilla Turelli, Dongchun Ni, Laurent H. Perez, Kelvin Lau, Erica Lana, Céline Pellaton, Charlène Raclot, Line Esteves-Leuenberger, Jérémy Campos et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
33. SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
    Andrew P. Hederman, Harini Natarajan, Joshua A. Wiener, Peter F. Wright, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd, Joel N. Blankson, Amihai Rottenstreich, Gila Zarbiv et al. · 2022 · medRxiv
34. SARS-CoV-2 humoral immunity in people living with HIV-1
    Boitumelo M. Motsoeneng, Jinal N. Bhiman, Simone I. Richardson, Penny L. Moore · 2024 · Trends in Immunology
35. Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions
    Krithika Muthuraman, Matthew J. Jackman, Yu Liang, Meghan E. Garrett, Hong Cui, Loan Vu Hong Nguyen, Danton Ivanochko, Chengjin Ye, Paula A. Pino, Amberlee Hicks et al. · 2025 · Journal of Virology
36. Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
    Julie M. Fox, Vicky Roy, Bronwyn M. Gunn, Glen Bolton, Daved H. Fremont, Galit Alter, Michael Diamond, Austin W. Boesch · 2023 · Frontiers in Immunology
37. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
    Marne Azarias-da-Silva, Pierre Nioche, Calaiselvy Soudaramourty, Anne Bull-Maurer, Mounira Tiouajni, Dechuan Kong, Ouafa Zghidi‐Abouzid, Morgane Picard, Ana Mendes‐Frias, André Santa Cruz et al. · 2023 · Science Advances
38. AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains
    Cristina Moldovan Loomis, Thomas Lahlali, Danielle Van Citters, Megan Sprague, Grégory Neveu, Laurence Somody, Christine C. Siska, Derrick Deming, Andrew Asakawa, Tileli Amimeur et al. · 2024 · Antibody Therapeutics
39. Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses
    Mireia Pelegrín, Soledad Marsile-Medun, Daouda Abba Moussa, Manon Souchard, Mar Naranjo‐Gómez · 2022 · Antibodies
40. Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys
    Jilei Jia, Zhaojuan Yin, Xiao Zhang, Huimin Li, Dan Meng, Qianqian Liu, Hongfang Wang, Meng Han, Shixiang Suo, Yan Liu et al. · 2022 · Pharmaceutical Research
41. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19
    Agustı́n Valenzuela-Fernández, Romina Cabrera-Rodríguez, Laura Ciuffreda, Silvia Pérez-Yanes, Judith Estévez‐Herrera, Rafaela González‐Montelongo, Julia Alcoba-Flórez, Rodrigo Trujillo‐González, Diego García-Martínez de Artola, Helena Gil-Campesino et al. · 2022 · Frontiers in Bioengineering and Biotechnology
42. Comparative Assessment of the Binding and Neutralisation Activity of Bispecific Antibodies Against SARS-CoV-2 Variants
    Alexis Q. Dean, Charles B. Stauft, Julianne D. Twomey, Joshua Tan, Luca Varani, Tony T. Wang, Baolin Zhang · 2022 · Antibody Therapeutics
43. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection
    Entao Li, Qiuxue Han, Jinhao Bi, Shimeng Wei, Shen Wang, Ying Zhang, Jun Liu, Na Feng, Tiecheng Wang, Jun Wu et al. · 2023 · Frontiers in Immunology
44. When a Calorie Is Not a Calorie: Metabolic and Molecular Effects of Intermittent Fasting in Humans; Exploratory Outcomes of a Randomized Clinical Trial
    Luigi Fontana, Valeria Tosti, Ruteja A. Barve, Beatrice Bertozzi, Nicola Veronese, Francesco Spelta, Edda Cava, Mark P. Mattson, Laura M. Piccio, Dayna S. Early et al. · 2023
45. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects
    Dhuha H Nawab · 2021 · Human Vaccines & Immunotherapeutics
46. Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents
    Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijałkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
47. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates
    Kizzmekia S. Corbett, Matthew Gagné, Danielle A. Wagner, Sarah O’ Connell, Sandeep Narpala, Dillon R. Flebbe, Shayne F. Andrew, Rachel L. Davis, Barbara J. Flynn, Timothy S. Johnston et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
48. Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
    Alexandra C. Walls, Kaitlin R. Sprouse, Anshu Joshi, John E. Bowen, Nicholas Franko, Mary Jane Navarro, Cameron Stewart, Matthew McCallum, Erin A. Goecker, Emily Degli-Angeli et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
49. Breadth of Fc-Mediated Effector Function Delineates Grades of Clinical Immunity Following Human Malaria Challenge
    Irene N. Nkumama, Dennis Odera, Fauzia K. Musasia, Kennedy Mwai, Lydia Nyamako, Linda Murungi, James Tuju, Kristin Fürle, Micha Rosenkranz, Rinter Kimathi et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
50. CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution
    Chuang Li, Jie Yu, Rahma Issa, Lili Wang, Mingzhe Ning, Shengxia Yin, Jie Li, Chao Wu, Yuxin Chen · 2024 · Emerging Microbes & Infections
51. Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages
    Suzanne Pickering, Harry Wilson, Enrico Bravo, Marianne R. Perera, Jeffrey Seow, Carl Graham, Nathalia Almeida, Lazaros Fotopoulos, Thomas Williams, Atlanta Moitra et al. · 2024 · Nature Communications
52. A systems biology approach to define SARS-CoV-2 correlates of protection
    Caolann Brady, Tom Tipton, Oliver T. Carnell, Stéphanie Longet, Karen E. Gooch, Yper Hall, Javier Salguero, Adriana Tomić, Miles W. Carroll · 2025 · npj Vaccines
53. One thousand SARS-CoV-2 antibody structures reveal convergent binding and near-universal immune escape
    Zirui Feng, Zhe Sang, Yufei Xiang, Alba Escalera, Adi Weshler, Dina Schneidman‐Duhovny, Adolfo García‐Sastre, Yi Shi · 2025 · Cell Systems
54. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
    Wenjuan Du, Rick Janssens, Anna Z. Mykytyn, Wentao Li, Dubravka Drabek, Rien van Haperen, Marianthi Chatziandreou, Melanie Rissmann, Joline van der Lee, Melissa van Dortmondt et al. · 2023 · Frontiers in Immunology
55. Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
    Rodrigo Lázaro‐Gorines, Patricia Pérez, Ignacio Heras‐Murillo, Irene Adán‐Barrientos, Guillermo Albericio, David Astorgano, Sara Flores, Joanna Luczkowiak, Nuria Labiod, Seandean L. Harwood et al. · 2023 · Advanced Science
56. Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy – a balancing act
    Hillary A. Vanderven, Stephen John Kent · 2023 · Frontiers in Immunology
57. Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope
    Michael Bick, Eduard Puig, David Beauparlant, Rebecca Nedellec, Iszac Burton, Keihvan Ardaghi, Thea R. Zalunardo, Raiza B. Bastidas, Xuduo Li, Javier Guenaga et al. · 2025 · Cell Reports
58. SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses
    Dennis Christensen, Charlotta Polacek, Daniel J. Sheward, Leo Hanke, Gerald M. McInerney, Ben Murrell, Katrine Top Hartmann, Henrik Elvang Jensen, Julie Zimmermann, Gregers Jungersen et al. · 2023 · Frontiers in Immunology
59. Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
    Matthias Hillenbrand, Christoph Esslinger, Jemima Seidenberg, Marcel Weber, Andreas Zingg, Catherine L. Townsend, Barbara Eicher, Justina Rutkauskaite, Peggy Riese, Carlos A. Guzmán et al. · 2024 · Viruses
60. Primary SARS‐CoV‐2 infection in children and adults results in similar Fc‐mediated antibody effector function patterns
    Anne T. Gelderloos, Anke J. Lakerveld, Rutger M. Schepp, Mioara Alina Nicolaie, Josine van Beek, Lisa Beckers, Rob S. van Binnendijk, Nynke Y. Rots, Puck B. van Kasteren · 2024 · Clinical & Translational Immunology
61. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
    D. Focosi, F. Maggi, M. Franchini, A. Aguzzi, M. Lanza, A. Mazzoni, F. Menichetti · 2021 · Clinical Microbiology and Infection
62. Passive Immunity Should and Will Work for COVID-19 for Some Patients
    Nevio Cimolai · 2021 · Clinical Hematology International
63. Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
    Paulina Kapłonek, Deniz Cizmeci, Jessica Shih-Lu Lee, Sally A. Shin, Stephanie Fischinger, Philipe Gobeil, Stéphane Pillet, Nathalie Charland, Brian J. Ward, Galit Alter · 2023 · npj Vaccines
64. Pre-clinical models to define correlates of protection for SARS-CoV-2
    Caolann Brady, Tom Tipton, Stéphanie Longet, Miles W. Carroll · 2023 · Frontiers in Immunology
65. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
    Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
66. Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2
    Samantha Mackin, Pritesh Desai, Bradley M. Whitener, Courtney E. Karl, Meizi Liu, Ralph Steven Baric, Darin K. Edwards, Taras M. Chicz, Ryan P. McNamara, Galit Alter et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
67. Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody
    Yi-Hsuan Chang, Min‐Feng Hsu, Wei-Nan Chen, Minhao Wu, Wye‐Lup Kong, Mei‐Yeh Jade Lu, Chih-Heng Huang, Fang-Ju Chang, Lan‐Yi Chang, Ho-Yang Tsai et al. · 2024 · JCI Insight
68. NK Cell and Monocyte Dysfunction in Multisystem Inflammatory Syndrome in Children
    Jenna K. Dick, Jules A. Sangala, Venkatramana Divana Krishna, Aaron Khaimraj, Lydia Hamel, Spencer M Erickson, Dustin M. Hicks, Yvette Soigner, Laura Covill, Alexander K. Johnson et al. · 2024 · The Journal of Immunology
69. Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
    Xiaohui Wei, Na Rong, Jiangning Liu · 2022 · Frontiers in Immunology
70. Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
    Aruni Jha, Douglas Barker, Jocelyne M. Lew, Vinoth K. Manoharan, Jill van Kessel, Robert E. Haupt, Derek Toth, Matthew B. Frieman, Darryl Falzarano, Shantha Kodihalli · 2022 · Scientific Reports
71. Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells
    Gladys J. Keitany, Benjamin E. Rubin, Meghan E. Garrett, Andrea Musa, Jeff Tracy, Yu Liang, Peter Ebert, Amanda J. Moore, Jonathan Guan, Erica L. Eggers et al. · 2023 · Cell chemical biology
72. Remote psychophysical testing of smell in patients with persistent olfactory dysfunction after COVID-19
    Marcela Martončíková, Pavel Doležal, Kamila Fabianová, Miloslav Karhánek, Ján Gálik, Adam Raček, Alexandra Popovičová, Enikö Račeková · 2023 · Scientific Reports
73. Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence
    Arman Izadi, Magdalena Godzwon, Anna Söderlund‐Strand, Tobias Schmidt, Susanna Kumlien Georén, Christian Drosten, Mats Ohlin, Pontus Nordenfelt · 2024 · The Journal of Immunology
74. Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics
    Robert V. House, Thomas A. Broge, Todd J. Suscovich, Doris M. Snow, Milan T. Tomic, Genevieve H. Nonet, Kamaljit Bajwa, Guangyu Zhu, Zachary Martinez, Kyal Hackett et al. · 2022 · PLoS ONE
75. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor
    S. Andrade, J. V. Batalha-Carvalho, R. Curi, Fan H. Wen, D. Covas, A. Chudzinski-Tavassi, A. M. Moro · 2022 · Frontiers in Immunology
76. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
    Kathryn McGuckin Wuertz, Erica K. Barkei, Wei-hung Chen, Elizabeth J. Martinez, Inès Lakhal-Naouar, Linda L. Jagodzinski, Dominic Paquin‐Proulx, Gregory D. Gromowski, Isabella Swafford, Akshaya Ganesh et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
77. Fc-effector functional antibody assays for SARS-CoV-2 variants of concern
    Xuemin Chen, Grace Li, Caroline Rose Ciric, Theda Gibson, Larry J. Anderson, Christina A. Rostad · 2025 · Frontiers in Immunology
78. Age-associated defect in ADCC response to COVID-19 vaccine
    Benjamin Louis Sievers, Mazharul Altaf, Mark T. K. Cheng, Kimia Kamelian, Claire Cormie, John R. Bradley, Stephen Baker, Barbara Graves, Hannah Stark, Sabine Hein et al. · 2025 · npj Vaccines
79. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies
    Erin Stefanutti, Rashmi Ramani, Bradley M. Whitener, Ha V. Dang, Simon Bélanger, Logeshwaran Somasundaram, Karen Cortina, Anna De Marco, Tommy Tam, Qingqing Chai et al. · 2025 · Microbiology Spectrum
80. Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design
    Jiale Zhang, Chuang Li, Yuanyuan Wu, Lili Wang, Jie Yu, Aofan Wang, Wenwen Kong, Mingzhe Ning, J M Chen, Yuxin Chen · 2026 · Frontiers in Immunology
81. Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients
    Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S. Kelkar, Pieter Pannus, Shilpee Sharma, Alexandra Waegemans, Véronique Olislagers, Daphnée Georges, Emilie Dhondt et al. · 2023 · Kidney International Reports
82. Characterization of antibody‐dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes
    Anurag Adhikari, Arunasingam Abayasingam, Nicholas A. Brasher, Ha Na Kim, Megan Susan Lord, David Agapiou, Lisa Maher, Chaturaka Rodrigo, Andrew R. Lloyd, Rowena Anne Bull et al. · 2024 · Journal of Medical Virology
83. A Significant Contribution of the Classical Pathway of Complement in SARS-CoV-2 Neutralization of Convalescent and Vaccinee Sera
    Patrick Budylowski, Serena Chau, Arinjay Banerjee, Furkan Guvenc, Reuben Samson, Queenie Hu, Lindsey K. Fiddes, Laurie A. Seifried, Gary Y. C. Chao, Megan Buchholz et al. · 2024 · The Journal of Immunology
84. Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
    Alexander W. Harris, Liriye Kurtovic, Jeane Nogueira, Isabel Cristina da Silva Bouzas, D. Herbert Opi, Bruce D. Wines, Wen Shi Lee, Philip Mark Hogarth, Pantelis Poumbourios, Heidi E. Drummer et al. · 2024 · Communications Medicine
85. BA.1 breakthrough infection elicits distinct antibody and memory B cell responses in vaccinated-only versus hybrid immunity individuals
    Carla Saade, Timothée Bruel, Lou-Léna Vrignaud, Martin Killian, Annabelle Drouillard, Véronique Barateau, Maxime Espi, Natacha Mariano, Charlotte Mignon, Lily Bruyère et al. · 2025 · iScience
86. Impact of Clinical and Genomic Factors on COVID-19 Disease Severity.
    Sanjoy Dey, Aritra Bose, Subrata Saha, Prithwish Chakraborty, Mohamed Ghalwash, Aldo Guzm X E N-Sáenz, Filippo Utro, Kenney Ng, Jianying Hu, Laxmi Parida et al. · 2021 · PubMed Central
87. The potency and synergy of plant‐made monoclonal antibodies against the BA.5 variant of SARS‐CoV‐2
    Haiyan Sun, Collin Jugler, Katherine Nguyen, Herta Steinkellner, Qiang Chen · 2022 · Plant Biotechnology Journal
88. Catalase associated with antagonistic changes of abscisic acid and gibberellin response, biosynthesis and catabolism is involved in eugenol-inhibited seed germination in rice
    Chi-Chieh Hu, Chin-Yu Wu, Min-Yu Yang, Jian-Zhi Huang, Chih-Wen Wu, Chwan‐Yang Hong · 2023 · Plant Cell Reports
89. Non-neutralizing antibodies against SARS-CoV-2 nucleocapsid protein mediate variant transcendent antibody-dependent cellular cytotoxicity
    Anthonia E Osuagwu, Michael Payne, Jürgen Bosch, Uri R. Mbonye, Kien Nguyen, Jonathan Karn, Anna M. Bruchez, Christopher L. King · 2025 · The Journal of Immunology
90. Effects of GSK3β inhibition in the regeneration of Syllis malaquini (Syllidae, Annelida)
    Rannyele Passos Ribeiro, M. Teresa Aguado · 2021 · Development Genes and Evolution
91. Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains
    Chuan Chen, James W. Saville, Michelle M. Martí, Alexandra Schäfer, Mary Hongying Cheng, Dhiraj Mannar, Xing Quan Zhu, Alison Berezuk, Anupam Banerjee, Michele D. Sobolewski et al. · 2022 · iScience
92. A linear B-cell epitope close to the furin cleavage site within the S1 domain of SARS-CoV-2 Spike protein discriminates the humoral immune response of nucleic acid- and protein-based vaccine cohorts
    Peter Lorenz, Felix Steinbeck, Franz Mai, Emil Christian Reisinger, Brigitte Müller‐Hilke · 2023 · Frontiers in Immunology
93. Cell-based passive immunization for protection against SARS-CoV-2 infection
    Evan Sawula, Shane Miersch, Eric D. Jong, Chengjin Li, Fang-Yu Chou, Jean Kit Tang, Reza Saberianfar, Jeffrey S. Harding, Sachdev S. Sidhu, András Nagy · 2023 · Stem Cell Research & Therapy
94. Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses
    Andrey Kruglov, Marina A. Bondareva, Violetta S. Gogoleva, Iaroslav K. Semin, Irina V. Astrakhantseva, Ruslan V. Zvartsev, Aleksandr S. Lunin, Vasiliy D. Apolokhov, Elena Yu. Shustova, Viktor P. Volok et al. · 2023 · European Journal of Immunology
95. The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19
    Солдатов Александр Алексеевич, Ж. И. Авдеева, Горенков Дмитрий Витальевич, L. M. Khantimirova, Yu.S. Paramonova, E.M. Smolina, В. П. Бондарев, Вадим Анатольевич Меркулов · 2022 · Immunologiya
96. Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit
    Маркина Ульяна Алексеевна, Daria S. Fomina, Лебедкина Марина Сергеевна, Tatiana S. Кruglova, Anton A. Chernov, Загребнева Алена Игоревна, Zinaida Yu. Mutovina, Alexander Viktorovich Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko · 2022 · Terapevticheskii arkhiv
97. Hybrid immunity elicits potent cross-variant ADCC against SARS-CoV-2 through a combination of anti-S1 and S2 antibodies
    Michael D. Grant, Kirsten Bentley, Ceri Alan Fielding, Keeley M. Hatfield, Danielle P. Ings, Debbie O. A. Harnum, Eddie C. Y. Wang, Richard James Stanton, Kayla A. Holder · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
98. CompBio and MIRaS – A Multi-omic Analysis Platform Built on a Memory-Based Intelligence Engine
    Ruteja A. Barve, Chad E. Storer, Wayne D Hoxsie, Curtis Marcum, Joshua F. McMichael, Jared M. Lalmansingh, Brittany K Smith, Mark R Johnson, Daniel J. Kuster, Richard D. Head · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
99. SARS-CoV-2 vaccines elicit differential Fc effector functions
    Nelia P. Manamela, Boitumelo M. Motsoeneng, Holly Spencer, Tandile Hermanus, Nonkululeko B. Mzindle, Frances Ayres, Zanele Makhado, Rudolph Serage, Glenda Gray, Linda‐Gail Bekker et al. · 2025 · iScience
100. Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates
     Benoît Levast, Jérémie Becker, Carla Saade, Inès VuDuc, Kendra Reynaud, Camilo Broc, Charlotte Mignon, Natacha Mariano, Stéphanie Donnat, Shin‐Yi Yu et al. · 2025 · npj Vaccines